-       Report 
- October 2025
-  185 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Clinical Trials 
- April 2025
-  280 Pages 
- Global 
   From       €2147EUR$2,400USD£1,888GBP 
      €2683EUR$3,000USD£2,360GBP 
          -       Report 
- June 2025
-  150 Pages 
- Global 
   From       €2414EUR$2,699USD£2,124GBP 
          -       Report 
- February 2025
-  60 Pages 
- Global 
   From       €8940EUR$9,995USD£7,864GBP 
            -       Report 
- February 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
                  Psychostimulants are a class of drugs that act on the central nervous system (CNS) to increase alertness, attention, and energy. They are commonly used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and are sometimes used off-label to treat depression and other conditions. Common psychostimulants include amphetamines, methylphenidate, and modafinil.
Psychostimulants work by increasing the levels of dopamine and norepinephrine in the brain, which can improve focus,    alertness, and energy. They can also increase heart rate and blood pressure, and can cause side effects such as insomnia, anxiety, and irritability.
The psychostimulants market is a subset of the larger CNS drugs market, which includes drugs used to treat a variety of neurological and psychiatric conditions. The psychostimulants market is expected to grow in the coming years due to increasing prevalence of ADHD and other conditions, as well as the development of new drugs.
Some companies in the psychostimulants market include Shire, Novartis, Johnson & Johnson, and Teva Pharmaceuticals. Show Less   Read more